These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
FORM 10-Q
|
||||
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
FUELCELL ENERGY, INC.
|
||||
|
(Exact name of registrant as specified in its charter)
|
||||
|
Delaware
|
|
06-0853042
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
3 Great Pasture Road
Danbury, Connecticut
|
|
06813
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (203) 825-6000
|
||||
|
Large accelerated filer
|
¨
|
Accelerated filer
|
ý
|
|
Non-accelerated filer
|
¨
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
¨
|
|
FUELCELL ENERGY, INC.
FORM 10-Q
Table of Contents
|
||
|
|
|
Page
|
|
PART I. FINANCIAL INFORMATION
|
|
|
|
Item 1.
|
|
|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
PART II. OTHER INFORMATION
|
|
|
|
Item 1
|
||
|
Item 1A
|
||
|
Item 6.
|
||
|
FUELCELL ENERGY, INC.
(Unaudited)
(Amounts in thousands, except share and per share amounts)
|
|||||||
|
|
July 31,
2012 |
|
October 31,
2011 |
||||
|
ASSETS
|
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
73,766
|
|
|
$
|
51,415
|
|
|
Investments — U.S. treasury securities
|
—
|
|
|
12,016
|
|
||
|
Accounts receivable, net
|
20,240
|
|
|
21,950
|
|
||
|
Inventories
|
48,995
|
|
|
40,101
|
|
||
|
Other current assets
|
6,084
|
|
|
7,466
|
|
||
|
Total current assets
|
149,085
|
|
|
132,948
|
|
||
|
Property, plant and equipment, net
|
22,450
|
|
|
23,925
|
|
||
|
Investment in and loans to affiliate
|
9,826
|
|
|
10,466
|
|
||
|
Other assets, net
|
15,672
|
|
|
16,291
|
|
||
|
Total assets
|
$
|
197,033
|
|
|
$
|
183,630
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
||||
|
Current liabilities:
|
|
|
|
||||
|
Current portion of long-term debt
|
$
|
5,126
|
|
|
$
|
5,056
|
|
|
Accounts payable
|
10,871
|
|
|
14,143
|
|
||
|
Accounts payable due to affiliate
|
324
|
|
|
104
|
|
||
|
Accrued liabilities
|
20,454
|
|
|
26,894
|
|
||
|
Deferred revenue
|
50,380
|
|
|
64,114
|
|
||
|
Preferred stock obligation of subsidiary
|
1,071
|
|
|
3,854
|
|
||
|
Total current liabilities
|
88,226
|
|
|
114,165
|
|
||
|
Long-term deferred revenue
|
6,250
|
|
|
7,000
|
|
||
|
Long-term preferred stock obligation of subsidiary
|
12,893
|
|
|
12,878
|
|
||
|
Long-term debt and other liabilities
|
4,028
|
|
|
4,105
|
|
||
|
Total liabilities
|
111,397
|
|
|
138,148
|
|
||
|
Redeemable preferred stock (liquidation preference of $64,020 at July 31, 2012 and October 31, 2011)
|
59,857
|
|
|
59,857
|
|
||
|
Total Equity (Deficit):
|
|
|
|
||||
|
Shareholders’ equity (deficit)
|
|
|
|
||||
|
Common stock ($.0001 par value); 275,000,000 shares authorized; 185,864,074 and 138,400,497 shares issued and outstanding at July 31, 2012 and October 31, 2011, respectively.
|
18
|
|
|
13
|
|
||
|
Additional paid-in capital
|
751,519
|
|
|
687,857
|
|
||
|
Accumulated deficit
|
(725,493
|
)
|
|
(701,336
|
)
|
||
|
Accumulated other comprehensive (loss) income
|
(65
|
)
|
|
15
|
|
||
|
Treasury stock, Common, at cost (5,679 shares at July 31, 2012 and October 31, 2011)
|
(53
|
)
|
|
(53
|
)
|
||
|
Deferred compensation
|
53
|
|
|
53
|
|
||
|
Total shareholders’ equity (deficit)
|
25,979
|
|
|
(13,451
|
)
|
||
|
Noncontrolling interest in subsidiaries
|
(200
|
)
|
|
(924
|
)
|
||
|
Total equity (deficit)
|
25,779
|
|
|
(14,375
|
)
|
||
|
Total liabilities and equity (deficit)
|
$
|
197,033
|
|
|
$
|
183,630
|
|
|
|
Three Months Ended July 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
Revenues (1):
|
|
|
|
||||
|
Product sales and revenues
|
$
|
27,569
|
|
|
$
|
29,382
|
|
|
Research and development contracts
|
2,124
|
|
|
1,778
|
|
||
|
Total revenues
|
29,693
|
|
|
31,160
|
|
||
|
Costs of revenues:
|
|
|
|
||||
|
Cost of product sales and revenues
|
30,321
|
|
|
29,133
|
|
||
|
Cost of research and development contracts
|
2,110
|
|
|
1,890
|
|
||
|
Total costs of revenues
|
32,431
|
|
|
31,023
|
|
||
|
Gross (loss) profit
|
(2,738
|
)
|
|
137
|
|
||
|
Operating expenses:
|
|
|
|
||||
|
Administrative and selling expenses
|
4,580
|
|
|
3,578
|
|
||
|
Research and development expenses
|
3,193
|
|
|
3,918
|
|
||
|
Total costs and expenses
|
7,773
|
|
|
7,496
|
|
||
|
Loss from operations
|
(10,511
|
)
|
|
(7,359
|
)
|
||
|
Interest expense
|
(544
|
)
|
|
(847
|
)
|
||
|
Loss from equity investment
|
(42
|
)
|
|
(94
|
)
|
||
|
License fee and royalty income
|
422
|
|
|
499
|
|
||
|
Other income (expense), net
|
656
|
|
|
(29
|
)
|
||
|
Loss before benefit for income taxes
|
(10,019
|
)
|
|
(7,830
|
)
|
||
|
Benefit for income taxes
|
9
|
|
|
—
|
|
||
|
Net loss
|
(10,010
|
)
|
|
(7,830
|
)
|
||
|
Net loss attributable to noncontrolling interest
|
88
|
|
|
76
|
|
||
|
Net loss attributable to FuelCell Energy, Inc.
|
(9,922
|
)
|
|
(7,754
|
)
|
||
|
Preferred stock dividends
|
(800
|
)
|
|
(800
|
)
|
||
|
Net loss to common shareholders
|
$
|
(10,722
|
)
|
|
$
|
(8,554
|
)
|
|
Loss per share basic and diluted:
|
|
|
|
||||
|
Net loss per share to common shareholders
|
$
|
(0.06
|
)
|
|
$
|
(0.07
|
)
|
|
Basic and diluted weighted average shares outstanding
|
185,906,834
|
|
|
126,923,550
|
|
||
|
(1)
|
Includes revenue from a related party. Refer to Concentrations in note 1 to the financial statements.
|
|
FUELCELL ENERGY, INC.
Consolidated Statements of Operations
(Unaudited)
(Amounts in thousands, except share and per share amounts)
|
|||||||
|
|
Nine Months Ended July 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
Revenues (1):
|
|
|
|
||||
|
Product sales and revenues
|
$
|
79,280
|
|
|
$
|
81,815
|
|
|
Research and development contracts
|
5,903
|
|
|
6,032
|
|
||
|
Total revenues
|
85,183
|
|
|
87,847
|
|
||
|
Costs of revenues:
|
|
|
|
||||
|
Cost of product sales and revenues
|
80,062
|
|
|
94,652
|
|
||
|
Cost of research and development contracts
|
5,554
|
|
|
6,244
|
|
||
|
Total costs of revenues
|
85,616
|
|
|
100,896
|
|
||
|
Gross loss
|
(433
|
)
|
|
(13,049
|
)
|
||
|
Operating expenses:
|
|
|
|
||||
|
Administrative and selling expenses
|
12,346
|
|
|
12,082
|
|
||
|
Research and development expenses
|
10,932
|
|
|
12,662
|
|
||
|
Total costs and expenses
|
23,278
|
|
|
24,744
|
|
||
|
Loss from operations
|
(23,711
|
)
|
|
(37,793
|
)
|
||
|
Interest expense
|
(1,749
|
)
|
|
(1,829
|
)
|
||
|
Loss from equity investment
|
(554
|
)
|
|
(149
|
)
|
||
|
License fee and royalty income
|
1,258
|
|
|
1,287
|
|
||
|
Other income (expense), net
|
438
|
|
|
173
|
|
||
|
Loss before redeemable preferred stock of subsidiary
|
(24,318
|
)
|
|
(38,311
|
)
|
||
|
Accretion of redeemable preferred stock of subsidiary
|
—
|
|
|
(525
|
)
|
||
|
Loss before provision for income taxes
|
(24,318
|
)
|
|
(38,836
|
)
|
||
|
Provision for income taxes
|
(69
|
)
|
|
(9
|
)
|
||
|
Net loss
|
(24,387
|
)
|
|
(38,845
|
)
|
||
|
Net loss attributable to noncontrolling interest
|
230
|
|
|
197
|
|
||
|
Net loss attributable to FuelCell Energy, Inc.
|
(24,157
|
)
|
|
(38,648
|
)
|
||
|
Adjustment for modification of redeemable preferred stock of subsidiary
|
—
|
|
|
(8,987
|
)
|
||
|
Preferred stock dividends
|
(2,401
|
)
|
|
(2,400
|
)
|
||
|
Net loss to common shareholders
|
$
|
(26,558
|
)
|
|
$
|
(50,035
|
)
|
|
Loss per share basic and diluted:
|
|
|
|
||||
|
Net loss per share to common shareholders
|
$
|
(0.17
|
)
|
|
$
|
(0.41
|
)
|
|
Basic and diluted weighted average shares outstanding
|
158,548,998
|
|
|
122,306,465
|
|
||
|
(1)
|
Includes revenue from a related party. Refer to Concentrations in note 1 to the financial statements.
|
|
|
Nine Months Ended July 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Net loss
|
$
|
(24,387
|
)
|
|
$
|
(38,845
|
)
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
|
Share-based compensation
|
1,517
|
|
|
2,049
|
|
||
|
Loss from equity investment
|
554
|
|
|
149
|
|
||
|
Accretion of redeemable preferred stock of subsidiary
|
—
|
|
|
525
|
|
||
|
Depreciation
|
4,174
|
|
|
4,813
|
|
||
|
Amortization of bond premium and interest expense on Series 1 Preferred
|
1,536
|
|
|
1,784
|
|
||
|
Other non-cash transactions
|
(191
|
)
|
|
114
|
|
||
|
Decrease (increase) in operating assets:
|
|
|
|
||||
|
Accounts receivable
|
1,725
|
|
|
1,221
|
|
||
|
Inventories
|
(8,894
|
)
|
|
(5,328
|
)
|
||
|
Other assets
|
2,147
|
|
|
(10,209
|
)
|
||
|
Increase (decrease) in operating liabilities:
|
|
|
|
||||
|
Accounts payable
|
(3,052
|
)
|
|
5,080
|
|
||
|
Accrued liabilities
|
(5,892
|
)
|
|
9,320
|
|
||
|
Deferred revenue
|
(14,484
|
)
|
|
11,316
|
|
||
|
Net cash used in operating activities
|
(45,247
|
)
|
|
(18,011
|
)
|
||
|
Cash flows from investing activities:
|
|
|
|
||||
|
Capital expenditures
|
(2,646
|
)
|
|
(1,175
|
)
|
||
|
Convertible loan to affiliate
|
—
|
|
|
(600
|
)
|
||
|
Treasury notes matured
|
12,000
|
|
|
49,000
|
|
||
|
Treasury notes purchased
|
—
|
|
|
(33,019
|
)
|
||
|
Net cash provided by investing activities
|
9,354
|
|
|
14,206
|
|
||
|
Cash flows from financing activities:
|
|
|
|
||||
|
Repayment of debt
|
(127
|
)
|
|
(232
|
)
|
||
|
Proceeds from debt
|
—
|
|
|
2,600
|
|
||
|
Proceeds received for noncontrolling interest in subsidiary
|
954
|
|
|
—
|
|
||
|
Payment of preferred dividends and return of capital
|
(6,506
|
)
|
|
(9,994
|
)
|
||
|
Proceeds from sale of common stock, net of registration fees
|
64,003
|
|
|
22,440
|
|
||
|
Net cash provided by financing activities
|
58,324
|
|
|
14,814
|
|
||
|
Effects on cash from changes in foreign currency rates
|
(80
|
)
|
|
4
|
|
||
|
Net increase in cash and cash equivalents
|
22,351
|
|
|
11,013
|
|
||
|
Cash and cash equivalents-beginning of period
|
51,415
|
|
|
20,467
|
|
||
|
Cash and cash equivalents-end of period
|
$
|
73,766
|
|
|
$
|
31,480
|
|
|
Supplemental cash flow disclosures:
|
|
|
|
||||
|
Cash interest paid
|
$
|
229
|
|
|
$
|
115
|
|
|
Noncash financing and investing activity:
|
|
|
|
||||
|
Common stock issued in settlement of prior year bonus obligation
|
$
|
550
|
|
|
$
|
707
|
|
|
Common stock issued for Employee Stock Purchase Plan in settlement of prior year accrued employee contributions
|
$
|
84
|
|
|
$
|
125
|
|
|
Adjustment for modification of redeemable preferred stock of subsidiary
|
$
|
—
|
|
|
$
|
8,987
|
|
|
|
Three Months Ended July 31,
|
Nine Months Ended July 31,
|
||||||||
|
|
2012
|
|
2011
|
2012
|
|
2011
|
||||
|
POSCO Energy
|
72
|
%
|
|
34
|
%
|
72
|
%
|
|
49
|
%
|
|
BioFuels Fuel Cells, LLC
|
1
|
%
|
|
19
|
%
|
—
|
%
|
|
16
|
%
|
|
UTS BioEnergy, LLC
|
—
|
%
|
|
15
|
%
|
2
|
%
|
|
6
|
%
|
|
U.S. Government
|
9
|
%
|
|
6
|
%
|
7
|
%
|
|
7
|
%
|
|
Combined
|
82
|
%
|
|
74
|
%
|
81
|
%
|
|
78
|
%
|
|
|
Three Months Ended July 31,
|
|
Nine Months Ended July 31,
|
||||||||||||
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
|
Net loss
|
$
|
(10,010
|
)
|
|
$
|
(7,830
|
)
|
|
$
|
(24,387
|
)
|
|
$
|
(38,845
|
)
|
|
Foreign currency translation adjustments
|
(78
|
)
|
|
—
|
|
|
(80
|
)
|
|
4
|
|
||||
|
Comprehensive loss
|
$
|
(10,088
|
)
|
|
$
|
(7,830
|
)
|
|
$
|
(24,467
|
)
|
|
$
|
(38,841
|
)
|
|
|
Amortized
cost
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
(losses)
|
|
Fair value
|
||||||||
|
U.S. government obligations
|
|
|
|
|
|
|
|
||||||||
|
As of July 31, 2012
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
As of October 31, 2011
|
$
|
12,016
|
|
|
$
|
14
|
|
|
$
|
—
|
|
|
$
|
12,030
|
|
|
|
July 31,
2012 |
|
October 31,
2011 |
||||
|
Raw materials
|
$
|
18,642
|
|
|
$
|
18,303
|
|
|
Work-in-process
(1)
|
30,353
|
|
|
21,798
|
|
||
|
Net Inventory
|
$
|
48,995
|
|
|
$
|
40,101
|
|
|
(1)
|
Work-in-process includes the standard components of inventory that are used to build the typical modules or stack components that are intended to be used in future power plant orders. Included in Work-in-process as of
July 31, 2012
is
$9.9 million
of completed standard components ready to be incorporated into power plants and deployed upon receipt of customer orders.
|
|
|
July 31, 2012
|
|
October 31, 2011
|
||||
|
U.S. Government:
|
|
|
|
||||
|
Amount billed
|
$
|
371
|
|
|
$
|
52
|
|
|
Unbilled recoverable costs
|
1,142
|
|
|
1,012
|
|
||
|
|
1,513
|
|
|
1,064
|
|
||
|
Commercial Customers:
|
|
|
|
||||
|
Amount billed
|
13,381
|
|
|
10,330
|
|
||
|
Unbilled recoverable costs
|
5,346
|
|
|
10,556
|
|
||
|
|
18,727
|
|
|
20,886
|
|
||
|
|
$
|
20,240
|
|
|
$
|
21,950
|
|
|
|
July 31, 2012
|
|
October 31, 2011
|
||||
|
Long-term stack residual value
(1)
|
$
|
14,530
|
|
|
$
|
15,092
|
|
|
Other
(2)
|
1,142
|
|
|
1,199
|
|
||
|
Other Assets, net
|
$
|
15,672
|
|
|
$
|
16,291
|
|
|
(1)
|
Relates to stack replacements performed under the Company's service agreements. The cost of the stack replacement is recorded as a long term asset and is depreciated over its expected life. If the Company does not obtain rights to title from the customer, the cost of the stack is expensed at the time of restack. Accumulated depreciation was
$6.9 million
and
$2.4 million
for the periods ended
July 31, 2012
and
October 31, 2011
, respectively.
|
|
(2)
|
Includes security deposits, notes receivable and interest receivable.
|
|
|
July 31, 2012
|
|
October 31, 2011
|
||||
|
Accrued payroll and employee benefits
(1)
|
$
|
3,396
|
|
|
$
|
4,672
|
|
|
Accrued contract and operating costs
(2)
|
44
|
|
|
88
|
|
||
|
Reserve for product warranty cost
(3)
|
1,197
|
|
|
1,134
|
|
||
|
Reserve for service agreement costs
(4)
|
9,429
|
|
|
11,096
|
|
||
|
Reserve for B1200 repair and upgrade program
(5)
|
4,365
|
|
|
7,949
|
|
||
|
Accrued taxes, legal, professional and other
(6)
|
2,023
|
|
|
1,955
|
|
||
|
|
$
|
20,454
|
|
|
$
|
26,894
|
|
|
(1)
|
Balance relates to amounts owed to employees for compensation and benefits as of the end of the period.
|
|
(2)
|
Balance includes estimated losses accrued on product sales contracts.
|
|
(3)
|
Activity in the reserve for product warranty costs for the
nine months ended July 31, 2012
included additions for estimates of potential future warranty obligations of
$0.5 million
on contracts in the warranty period and reserve reductions related to actual warranty spend and reversals to income of
$0.4 million
as contracts progress through the warranty period or are beyond the warranty period.
|
|
(4)
|
As of
July 31, 2012
, the loss reserve on service agreement contracts totaled
$6.9 million
compared to
$8.9 million
as of
October 31, 2011
.
Also included in this line item is a reserve for performance guarantees penalties under the terms of our customer contracts, which based on our ongoing analysis of historical fleet performance totaled
$2.5 million
and
$2.2 million
as of
July 31, 2012
and
October 31, 2011
, respectively.
|
|
(5)
|
For the
nine months ended July 31, 2012
, the Company incurred actual repair and upgrade costs of approximately
$3.6 million
.
|
|
(6)
|
Balance includes accrued sales, use and payroll taxes as well as accrued legal, professional and other expenses as of the end of the period.
|
|
|
Three Months Ended July 31,
|
|
Nine Months Ended July 31,
|
||||||||||||
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
|
Cost of product sales and revenues
|
$
|
153
|
|
|
$
|
201
|
|
|
$
|
369
|
|
|
$
|
604
|
|
|
Cost of research and development contracts
|
29
|
|
|
34
|
|
|
66
|
|
|
105
|
|
||||
|
General and administrative expense
|
416
|
|
|
98
|
|
|
873
|
|
|
989
|
|
||||
|
Research and development expense
|
76
|
|
|
108
|
|
|
208
|
|
|
349
|
|
||||
|
Total share-based compensation
|
$
|
674
|
|
|
$
|
441
|
|
|
$
|
1,516
|
|
|
$
|
2,047
|
|
|
|
Number of
options
|
|
Weighted
average
option price ($)
|
||
|
Outstanding at October 31, 2011
|
3,320,558
|
|
|
8.25
|
|
|
Granted
|
342,293
|
|
|
1.28
|
|
|
Cancelled
|
(506,045
|
)
|
|
11.42
|
|
|
Outstanding at July 31, 2012
|
3,156,806
|
|
|
7.05
|
|
|
|
Total
Shareholders’
Equity (Deficit)
|
|
Noncontrolling
interest
|
|
Total
Equity (Deficit)
|
||||||
|
Balance at October 31, 2011
|
$
|
(13,451
|
)
|
|
$
|
(924
|
)
|
|
$
|
(14,375
|
)
|
|
Sale of Common Stock and related fees
|
64,003
|
|
|
—
|
|
|
64,003
|
|
|||
|
Share-based compensation
|
1,517
|
|
|
—
|
|
|
1,517
|
|
|||
|
Common stock issued in settlement of prior year bonus obligation
|
550
|
|
|
—
|
|
|
550
|
|
|||
|
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards
|
(2
|
)
|
|
—
|
|
|
(2
|
)
|
|||
|
Sale of noncontrolling interest in subsidiary
|
—
|
|
|
954
|
|
|
954
|
|
|||
|
Preferred dividends – Series B
|
(2,401
|
)
|
|
—
|
|
|
(2,401
|
)
|
|||
|
Other comprehensive loss - foreign currency translation adjustments
|
(80
|
)
|
|
—
|
|
|
(80
|
)
|
|||
|
Net loss
|
(24,157
|
)
|
|
(230
|
)
|
|
(24,387
|
)
|
|||
|
Balance at July 31, 2012
|
$
|
25,979
|
|
|
$
|
(200
|
)
|
|
$
|
25,779
|
|
|
|
Three Months Ended July 31,
|
|
Nine Months Ended July 31,
|
||||||||||||
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
|
Numerator
|
|
|
|
|
|
|
|
||||||||
|
Net loss
|
$
|
(10,010
|
)
|
|
$
|
(7,830
|
)
|
|
$
|
(24,387
|
)
|
|
$
|
(38,845
|
)
|
|
Net loss attributable to noncontrolling interest
|
88
|
|
|
76
|
|
|
230
|
|
|
197
|
|
||||
|
Modification of redeemable preferred stock of subsidiary
|
—
|
|
|
—
|
|
|
—
|
|
|
(8,987
|
)
|
||||
|
Preferred stock dividend
|
(800
|
)
|
|
(800
|
)
|
|
(2,401
|
)
|
|
(2,400
|
)
|
||||
|
Net loss to common shareholders
|
$
|
(10,722
|
)
|
|
$
|
(8,554
|
)
|
|
$
|
(26,558
|
)
|
|
$
|
(50,035
|
)
|
|
Denominator
|
|
|
|
|
|
|
|
||||||||
|
Weighted average basic common shares
|
185,906,834
|
|
|
126,923,550
|
|
|
158,548,998
|
|
|
122,306,465
|
|
||||
|
Effect of dilutive securities
(1)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
|
Weighted average diluted common shares
|
185,906,834
|
|
|
126,923,550
|
|
|
158,548,998
|
|
|
122,306,465
|
|
||||
|
Basic loss per share
|
$
|
(0.06
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.17
|
)
|
|
$
|
(0.41
|
)
|
|
Diluted loss per share (1)
|
$
|
(0.06
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.17
|
)
|
|
$
|
(0.41
|
)
|
|
(1)
|
Diluted loss per share was computed without consideration to potentially dilutive instruments as their inclusion would have been antidilutive, as the strike prices are above current market price. Potentially dilutive instruments include stock options, warrants and convertible preferred stock. At
July 31, 2012 and 2011
, there were options to purchase
3.2 million
and
3.9 million
shares of common stock, respectively. There were outstanding warrants for the right to purchase
10.2 million
shares as of
July 31, 2012 and 2011
, respectively. Refer to our Annual Report on Form 10-K for the year ended
October 31, 2011
for information on our convertible preferred stock.
|
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
|
Three Months Ended
July 31,
|
|
Change
|
|||||||||||
|
|
2012
|
|
2011
|
|
$
|
|
%
|
|||||||
|
Revenues:
|
|
|
|
|
|
|
|
|||||||
|
Product sales and revenues
|
$
|
27,569
|
|
|
$
|
29,382
|
|
|
$
|
(1,813
|
)
|
|
(6
|
)
|
|
Research and development contracts
|
2,124
|
|
|
1,778
|
|
|
346
|
|
|
19
|
|
|||
|
Total
|
$
|
29,693
|
|
|
$
|
31,160
|
|
|
$
|
(1,467
|
)
|
|
(5
|
)
|
|
Cost of revenues:
|
|
|
|
|
|
|
|
|||||||
|
Product sales and revenues
|
$
|
30,321
|
|
|
$
|
29,133
|
|
|
$
|
1,188
|
|
|
4
|
|
|
Research and development contracts
|
2,110
|
|
|
1,890
|
|
|
220
|
|
|
12
|
|
|||
|
Total
|
$
|
32,431
|
|
|
$
|
31,023
|
|
|
$
|
1,408
|
|
|
5
|
|
|
Gross profit (loss):
|
|
|
|
|
|
|
|
|||||||
|
Gross profit (loss) from product sales and revenues
|
$
|
(2,752
|
)
|
|
$
|
249
|
|
|
$
|
(3,001
|
)
|
|
(1,205
|
)
|
|
Gross profit (loss) from research and development contracts
|
14
|
|
|
(112
|
)
|
|
126
|
|
|
(113
|
)
|
|||
|
Total
|
$
|
(2,738
|
)
|
|
$
|
137
|
|
|
$
|
(2,875
|
)
|
|
(2,099
|
)
|
|
Product Sales Cost-to-revenue ratio
(1)
|
1.10
|
|
|
0.99
|
|
|
|
|
11
|
|
||||
|
|
Nine Months Ended
July 31,
|
|
Change
|
|||||||||||
|
|
2012
|
|
2011
|
|
$
|
|
%
|
|||||||
|
Revenues:
|
|
|
|
|
|
|
|
|||||||
|
Product sales and revenues
|
$
|
79,280
|
|
|
$
|
81,815
|
|
|
$
|
(2,535
|
)
|
|
(3
|
)
|
|
Research and development contracts
|
5,903
|
|
|
6,032
|
|
|
(129
|
)
|
|
(2
|
)
|
|||
|
Total
|
$
|
85,183
|
|
|
$
|
87,847
|
|
|
$
|
(2,664
|
)
|
|
(3
|
)
|
|
Cost of revenues:
|
|
|
|
|
|
|
|
|||||||
|
Product sales and revenues
|
$
|
80,062
|
|
|
$
|
94,652
|
|
|
$
|
(14,590
|
)
|
|
(15
|
)
|
|
Research and development contracts
|
5,554
|
|
|
6,244
|
|
|
(690
|
)
|
|
(11
|
)
|
|||
|
Total
|
$
|
85,616
|
|
|
$
|
100,896
|
|
|
$
|
(15,280
|
)
|
|
(15
|
)
|
|
Gross profit (loss):
|
|
|
|
|
|
|
|
|||||||
|
Gross loss from product sales and revenues
|
$
|
(782
|
)
|
|
$
|
(12,837
|
)
|
|
$
|
12,055
|
|
|
(94
|
)
|
|
Gross profit (loss) from research and development contracts
|
349
|
|
|
(212
|
)
|
|
561
|
|
|
(265
|
)
|
|||
|
Total
|
$
|
(433
|
)
|
|
$
|
(13,049
|
)
|
|
$
|
12,616
|
|
|
(97
|
)
|
|
Product Sales Cost-to-revenue ratio
(1)
|
1.01
|
|
|
1.16
|
|
|
|
|
(13
|
)
|
||||
|
(1)
|
Cost-to-revenue ratio is calculated as cost of product sales and revenues divided by product sales and revenues.
|
|
|
Payments Due by Period
|
||||||||||||||||||
|
|
Total
|
|
Less
than 1
Year
|
|
1 – 3
Years
|
|
3 – 5
Years
|
|
More
than
5 Years
|
||||||||||
|
Purchase commitments
(1)
|
$
|
58,346
|
|
|
$
|
53,961
|
|
|
$
|
4,385
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Series 1 Preferred obligation
(2)
|
14,700
|
|
|
1,245
|
|
|
2,490
|
|
|
2,490
|
|
|
8,474
|
|
|||||
|
Term loans (principal and interest)
|
4,358
|
|
|
1,022
|
|
|
416
|
|
|
460
|
|
|
2,460
|
|
|||||
|
Capital and operating lease commitments
(3)
|
2,740
|
|
|
982
|
|
|
1,571
|
|
|
187
|
|
|
—
|
|
|||||
|
Revolving Credit Facility
(4)
|
4,000
|
|
|
4,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Series B Preferred dividends payable
(5)
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Totals
|
$
|
84,144
|
|
|
$
|
61,210
|
|
|
$
|
8,862
|
|
|
$
|
3,137
|
|
|
$
|
10,934
|
|
|
(1)
|
Purchase commitments with suppliers for materials, supplies and services incurred in the normal course of business.
|
|
(2)
|
On March 31, 2011, the Company entered into an agreement with Enbridge, Inc. (“Enbridge”) to modify the Class A Cumulative Redeemable Exchangeable Preferred Share Agreement (the “Series 1 Preferred Share Agreement”). The terms of the Series 1 preferred share agreement require payments of (i) an annual amount of Cdn$500,000 for dividends and (ii) an amount of Cdn.$750,000 as return of capital payments payable in cash. These payments commenced on March 31, 2011 and will end on December 31, 2020. Dividends accrue at a 1.25% quarterly rate on the unpaid principal balance, and additional dividends will accrue on the cumulative unpaid dividends (inclusive of the Cdn.$12.5 million unpaid dividend balance as of the modification date) at a rate of 1.25% per quarter, compounded quarterly. On December 31, 2020 the amount of all accrued and unpaid dividends on the Class A Preferred Shares of Cdn$21.1 million and the balance of the principal redemption price of Cdn.$4.4 million will be due to the holders of the Series 1 preferred shares. The Company has the option of making dividend payments in the form of common stock or cash under terms outlined in the preferred share agreement. For purposes of preparing the above table, the final balance of accrued and unpaid dividends due December 31, 2020 of Cdn.$21.1 million is assumed to be paid in the form of common stock and not included in this table.
|
|
(3)
|
Future minimum lease payments on capital and operating leases.
|
|
(4)
|
The amount represents the amount outstanding as of July 31, 2012 on a $5.0 million revolving credit facility with JPMorgan Chase Bank, N.A. and the Export-Import Bank of the United States. The credit facility is to be used for working capital to finance the manufacture and production and subsequent export sale of the Company’s products or services. The agreement has a one year term with renewal provisions and the current expiration date is April 3, 2013. The outstanding principal balance of the facility will bear interest, at the option of the Company of either the one-month LIBOR plus 1.5 percent or the prime rate of JP Morgan Chase. The facility is secured by certain working capital assets and general intangibles, up to the amount of the outstanding facility balance.
|
|
(5)
|
We are currently paying $3.2 million in annual dividends on our Series B Preferred Stock. The $3.2 million annual dividend payment has not been included in this table as we cannot reasonably determine the period when or if we will be able to convert the Series B Preferred Stock into shares of our common stock. We may, at our option, convert these shares into the number of shares of our common stock that are issuable at the then prevailing conversion rate if the closing price of our common stock exceeds 150 percent of the then prevailing conversion price ($11.75) for 20 trading days during any consecutive 30 trading day period.
|
|
•
|
The delivered item or items have value to the customer on a standalone basis.
|
|
•
|
If the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item or items is considered probable and substantially in the control of the vendor.
|
|
Item 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
|
Item 4.
|
CONTROLS AND PROCEDURES
|
|
Item 1.
|
LEGAL PROCEEDINGS
|
|
Item 1A.
|
RISK FACTORS
|
|
Item 6.
|
EXHIBITS
|
|
Exhibit No.
|
|
Description
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS#
|
|
XBRL Instance Document
|
|
101.SCH#
|
|
XBRL Schema Document
|
|
101.CAL#
|
|
XBRL Calculation Linkbase Document
|
|
101.LAB#
|
|
XBRL Labels Linkbase Document
|
|
101.PRE#
|
|
XBRL Presentation Linkbase Document
|
|
101.DEF#
|
|
XBRL Definition Linkbase Document
|
|
|
|
FUELCELL ENERGY, INC.
|
|
|
|
(Registrant)
|
|
September 7, 2012
|
|
/s/ Michael S. Bishop
|
|
Date
|
|
Michael S. Bishop
Senior Vice President, Chief Financial Officer,
Treasurer and Corporate Secretary
(Principal Financial Officer and Principal Accounting Officer)
|
|
Exhibit
No.
|
|
Description
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
|
XBRL Schema Document
|
|
101.CAL
|
|
XBRL Calculation Linkbase Document
|
|
101.LAB
|
|
XBRL Labels Linkbase Document
|
|
101.PRE
|
|
XBRL Presentation Linkbase Document
|
|
101.DEF
|
|
XBRL Definition Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|